Abstract
Abstract
Background
124I Iodine (T$$_{1/2}$$
1
/
2
= 4.18 d) is the only long-life positron emitter radioisotope of iodine that may be used for both imaging and therapy as well as for 131I dosimetry. Its physical characteristics permits taking advantages of the higher Positron Emission Tomography (PET) image quality, whereas the availability of new molecules to be targeted with 124I makes it a novel innovative radiotracer probe for a specific molecular targeting.
Results
In this study Monte Carlo and SRIM/TRIM modelling was applied to predict the nuclear parameters of the 124I production process in a small medical cyclotron IBA 18/9 Cyclone. The simulation production yields for 124I and the polluting radioisotopes were calculated for the natural and enriched 124TeO2 + Al2O3 solid targets irradiated with 14.8 MeV protons. The proton beam was degraded energetically from 18 MeV with 0.2 mm Havar foil. The 124Te(p,xn)124I reactions were taken into account in the simulations. The optimal thickness of the target material was calculated using the SRIM/TRIM and Geant4 codes. The results of the simulations were compared with the experimental data obtained for the natural TeO2 +Al2O3 target. The dry distillation technique of the 124-iodine was applied.
Conclusions
The experimental efficiency for the natural Te target was better than 41% with an average thick target (>0.8 mm) yield of 1.32 MBq/μAh. Joining the Monte Carlo and experimental approaches makes it possible to optimize the methodology for the 124I production from the expensive Te enriched targets.
Funder
Politechnika Ślaska
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference63 articles.
1. Vaquero JJ, Kinahan P. Positron emission tomography: current challenges and opportunities for technological advances in clinical and preclinical imaging systems. Annu Rev Biomed Eng. 2015;17:385–414.
2. Happel C, Kranert WT, Ackermann H, Binse I, Bockisch B, Gröner D, Herrmann K, Grüwald F. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases. Endocrine. 2019;63:537–44.
3. Foss CA, Plyku D, Ordonez AA, Sanchez-Bautista J, Rosenthal HB, Il Minn, Lodge MA, Pomper MG, Sgouros G, Jain AK. Biodistribution and radiation dosimetry of 124 I-DPA-713, a PET radiotracer for macrophage-associated inflammation. J Nuclear Med. 2018;59:1751–6.
4. Kumar K, Ghosh A. Radiochemistry, production process, labeling, methods and immunoPET imaging pharmaceuticals of iodine-124. Molecules. 2021;26(2):414.
5. Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M. EANM position on the in-house preparation of radiopharmaceuticals. Eur J Nuclear Med Mol Imaging. 2022;1:1.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献